The significant reduction in myocardial fibrosis, measured by ECV, supports the growing body of evidence that SGLT2 inhibitors modulate adverse cardiac remodeling beyond their traditional metabolic benefits. Here, SLC5A2 is linked to Myocardial fibrosis.